Available Drugs for testing
Our catalog includes over 100 FDA-approved drugs.
Select a drug category to view the respective available therapies for testing
-
Azacitidine
Blinatumomab
Cladribine
Clofarabine
Crenolanib
Cytarabine
Cytarabine+ Mitoxantrone
Daunorubicin
Decitabine
Gilterinib
Idarubicin
Idasanutlin
Midostaurin
Mitoxantrone
Nilotinib
Panobinostat
Quizartinib
RG-7112
Siremadlin
Sorafenib
Venetoclax
-
4-OH Tamoxifen
Bleomycin HCl
Carboplatin
Cisplatin
Cycloheximide
Cyclophosphamide
Docetaxel
Doxorubicin
Epirubicin
Etoposide
Fluorouracil (5-FU)
FOLFIRI
FOLFOX
Gemcitabine
Ifosfamide
Irinotecan (SN-38)
Ixabepilone
Methotrexate
Oxaliplatin
Paclitaxel
Pemetrexed
Tipiracil
Vinorelbine
Vismodegib
-
Binimetinib
Bortezomib
Carfilzomib
Dabrafenib
Daratumumab
Dexamethasone
Encorafenib
Etoposide
Ixazomib
Lenalidomide
Cyclophosphamide
Melphalan
MMAF
Pomalidomide
Regorafenib
Selinexor
Trametinib
Venetoclax
-
Abemaciclib
Afatinib
Alectinib
Alpelisib
Axitinib
Bendamustine HCl
Bosutinib
Brigatinib
Cabazitaxel
Cabozantinib
Capmatinib
Ceritinib
Cobimetinib
Crizotinib
Dabrafenib
Dacomitinib
Dasatinib
Encorafenib
Entrectinib
Erlotinib
Everolimus
Gefitinib
Imatinib
Lapatinib
Larotrectinib
Mitomycin
Mobocertinib
Neratinib
Olaparib
Osimertinib
Panobinostat
Pazopanib
Ponatinib
Ribociclib
Sunitinib
Talazoparib
Topotecan
Trametinib
Vandetanib
Vemurafenib
Vinblastine
Vincristine Sulfate
NOTES AND ADDITIONAL INFORMATION:
Cyclophosphamide requires metabolic activation in vivo. In order to test for cell sensitivity in vitro, we use mafosfamide (aka maphosphamide), a cyclophosphamide analog that spontaneously hydrolyzes to the same active products.
FOLFIRINOX is a combination of folinic acid (Leucovorin) “FOL”, fluorouracil (5-FU) “F”, irinotecan (Camptosar) “IRIN”, and oxaliplatin (Eloxatin) "OX".
FOLFOX is a combination of folinic acid (Leucovorin) "FOL", fluorouracil (5-FU) "F", and oxaliplatin (Eloxatin) "OX".
Testing the IMiDs (including lenalidomide and pomalidomide) as monotherapies do not reliably produce mass response results that predict patient outcomes.
You can order up to 20 FDA-approved drugs of your choice with Travera RTS™.
Alternatively, Travera provides predetermined drug panels for each supported indication with Travera EarlyAccess™.
Limitations of the Early Access Program
The Travera EarlyAccess™ and the Travera RTS™ tests are available as a part of a temporary Early Access Program.
We want to be fully transparent about the following limitations and potential risks:
We do not receive enough live cells and can’t test the entire panel of 20 drugs.
Shipping delays result in the death of cancer cells. The sample would be rejected.
We have limited clinical evidence to date (all preliminary clinical studies have been promising and the evidence is growing)
Our catalog is growing but does not yet include all FDA-approved cancer drugs.
We do not address sarcomas and lymphomas yet.
We do not test pediatric cancers (for patients under 18 years old).